FrancophonIA/ELRC3.0 huggingface dataset:
English: The following side effects are very common (affects more than 1 patient in 10):
Slovenian: Naslednji neželeni učinki so zelo pogosti (pojavijo se pri več kot 1 od 10 bolnikov):
English: Sustained IgG trough levels with mean concentrations of 7.99 - 8.25 g/l were thereby achieved throughout the treatment period.
Slovenian: Dolgotrajne najnižje ravni IgG s srednjimi koncentracijami 7,99-8,25 g/l so se vzdrževale v celotnem obdobju zdravljenja.
English: If you have any further questions on the use of this medicine, please ask your doctor or healthcare professional.
Slovenian: Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali zdravstvenim delavcem.
English: The recommended initial infusion rate is up to 0.5 ml/min/site (30 ml/hour/site).
Slovenian: Priporočena začetna hitrost infundiranja je do 0,5 ml/min/mesto (30 ml/uro/mesto).
English: After steady state IgG levels have been attained, maintenance doses are administered at repeated intervals to reach a cumulative monthly dose of the order of 0.4 to 0.8 g/kg (2.0 to 4.0 ml/kg) body weight.
Slovenian: Ko je doseženo stanje dinamičnega ravnovesja ravni IgG, se dajejo vzdrževalni odmerki v ponavljajočih se presledkih, da se doseže kumulativni mesečni odmerek od 0,4 do 0,8 g/kg (2,0 do 4,0 ml/kg) telesne mase.
English: Clean the stopper with an alcohol wipe or antiseptic preparation and allow it to dry.
Slovenian: Obrišite zamašek z alkoholnim zložencem ali drugo antiseptično raztopino in pustite, da se posuši na zraku.
English: In the European pivotal prospective open label, single arm and multicentre study, a total of 51 subjects with primary immunodeficiency syndromes aged between 3 and 60 years old were treated with Hizentra for up to 41 weeks.
Slovenian: V evropski osrednji prospektivni, odprti, enokračni in multicentrični študiji so skupno 51 preiskovancev s sindromi primarne imunske pomanjkljivosti, starih od 3 do 60 let, zdravili z zdravilom Hizentra v obdobju do 41 tednov.
English: Grip strength, MRC sum score, and R-ODS centile score remained stable as compared to baseline for patients who never had a relapse in the extension study.
Slovenian: Moč stiska, skupna ocena mišične moči MRC (Medical Research Council) in ocena centilne vrednosti po lestvici R-ODS (Rasch-built Overall Disability Scale) so ostale stabilne v primerjavi z izhodiščnimi vrednostmi pri bolnikih, ki v podaljšani študiji nikoli niso imeli relapsa.
English: Human normal immunoglobulin 200 mg IgG .......................................... ≥ 98% IgA .......................... ≤ 50 micrograms
Slovenian: 1 ml vsebuje: humani polispecifični imunoglobulin ........... 200 mg IgG .............................................................. ≥ 98 % IgA .............................................................. ≤ 50 mikrogramov
English: Thereafter, if the patient tolerates the initial infusions at the full dose per site and maximum rate, an increase in the infusion rate of successive infusions may be considered at the discretion of the patient and based on the healthcare professionals' judgement.
Slovenian: Po tem lahko pri bolnikih, ki so začetno infundiranje polnega odmerka na posameznem mestu in pri največji hitrosti, dobro prenašali, razmislimo o povečanju hitrosti infundiranja naslednjih infundiranj po lastni presoji bolnika in na podlagi presoje zdravstvenega delavca.
English: Patients should be sufficiently hydrated before use of immunoglobulins.
Slovenian: Pred uporabo imunoglobulinov morajo biti bolniki ustrezno hidrirani.
English: Hizentra belongs to the class of medicines called human normal immunoglobulins.
Slovenian: Zdravilo Hizentra spada v skupino zdravil, ki se imenujejo humani polispecifični imunoglobulini.
English: Immunoglobulins are produced by human body's immune system.
Slovenian: Imunoglobuline proizvaja imunski sistem pri človeku.
English: Discard any unused product and all used administration supplies after administration in accordance with local requirements.
Slovenian: Neuporabljeno zdravilo in vse uporabljene pripomočke za dajanje zdravila po apliciranju zavrzite v skladu z lokalnimi predpisi.
English: No clinical studies have been performed with Hizentra in pregnant women.
Slovenian: Zdravilo Hizentra ni bilo klinično preizkušeno pri nosečnicah.
English: When only considering relapse, the CIDP relapse rates were 19.0 % for 0.4 g/kg bw Hizentra and 33.3 % for 0.2 g/kg bw Hizentra compared with 56.1 % for placebo (p < 0.001 or p = 0.012, respectively).
Slovenian: Ob upoštevanju samo relapsa so bile stopnje relapsa CIDP 19,0 % za odmerek zdravila Hizentra 0,4 g/kg TM in 33,3 % za odmerek 0,2 g/kg TM, v primerjavi s 56,1 % za placebo (p < 0,001 oziroma p = 0,012).
English: In the first patient group receiving Hizentra via the manual push technique (n=16), 2 to 7 infusions per week were administered with the flow rates of 30, 60 and 120 ml/hour/site (see section 4.2).
Slovenian: V prvi skupini bolnikov, ki so dobivali zdravilo Hizentra s tehniko ročnega potiskanja (n=16), je bilo 2 do 7 infuzij na teden apliciranih s hitrostmi infundiranja 30, 60 in 120 ml/uro/mesto (glejte poglavje 4.2).
English: After administration of this medicinal product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines.
Slovenian: Po uporabi tega zdravila morajo pred cepljenjem z živimi oslabljenih virusnimi cepivi preteči vsaj 3 meseci.
English: Data from prospective clinical trials on the use of human normal immunoglobulin in pregnant women is limited.
Slovenian: Podatki iz prospektivnih kliničnih preskušanj o uporabi humanega polispecifičnega imunoglobulina pri nosečnicah so omejeni.
English: In the second patient group receiving Hizentra via pump-assisted administration (n=18), weekly Hizentra infusions were administered with 25, 50, 75 and 100 ml/hour/site flow rate.
Slovenian: V drugi skupini bolnikov, ki so dobivali zdravilo Hizentra s pomočjo infuzijske črpalke (n=18), so bile tedenske infuzije zdravila Hizentra aplicirane s hitrostmi infundiranja 25, 50, 75 in 100 ml/uro/mesto.
English: Other important information about Hizentra
Slovenian: Ostale pomembne informacije o zdravilu Hizentra Krvne preiskave
English: The mean duration of exposure was 118.9 days in the 0.2 g/kg bw and 129 days in the 0.4 g/kg bw Hizentra group (maximum exposure up to 167 and 166 days in each group, respectively).
Slovenian: Povprečno trajanje izpostavljenosti zdravilu Hizentra je bilo za odmerek 0,2 g/kg TM 118,9 dni, za odmerek 0,4 g/kg TM pa 129 dni (največja izpostavljenost do 167 oziroma 166 dni v vsaki skupini).
English: Immunomodulatory therapy in CIDP patients
Slovenian: Imunomodulacija pri bolnikih s CIDP
English: Time to CIDP relapse (Figure 1) was evaluated, and the corresponding probabilities for CIDP relapse based on Kaplan-Meier estimates were: placebo, 58.8 %; 0.2 /kg bw Hizentra, 35.0 %; and 0.4 g/kg bw Hizentra, 22.4 %.
Slovenian: Ovrednotili so čas do relapsa CIDP (Slika 1) in ustrezne verjetnosti ponovitev CIDP, na osnovi ocen po metodi Kaplan-Meier, so bile: placebo, 58,8 %; zdravilo Hizentra 0,2 g/kg TM, 35,0 %; in zdravilo Hizentra 0,4 g/kg TM, 22,4 %.
English: The weekly dose can be divided into smaller doses and administered by desired number of times per week.
Slovenian: Tedenski odmerek lahko razdelimo na manjše odmerke, ki jih dajemo z želeno pogostnostjo tekom tedna.
English: Elderly population The same interactions may occur in the elderly population.
Slovenian: Starejša populacija Enaka medsebojna delovanja se lahko pojavijo pri starejši populaciji.
English: The mean efficacy evaluation period was 125.8 days (range: 1-330) in the 0.2 g/kg, and 196.1 days (range: 1-330) in the 0.4 g/kg bw group.
Slovenian: Srednje obdobje ovrednotenja učinkovitosti je bilo 125,8 dni (razpon: 1-330) v skupini, ki je prejemala odmerek 0,2 g/kg, in 196,1 dan (razpon: 1-330) v skupini, ki je prejemala odmerek 0,4 g/kg telesne mase.
English: No clinically relevant differences in the serum IgG trough concentrations were observed between the baseline at day 1 and the end of the study in all subjects.
Slovenian: Pri nobenem od preiskovancev niso ugotovili klinično pomembnih razlik med izhodiščnimi vrednostmi najnižjih plazemskih koncentracij IgG na 1. dan in vrednostmi le-teh ob koncu študije.
English: One ml contains 200 mg of human normal immunoglobulin, of which at least 98% is immunoglobulin type G (IgG).
Slovenian: En mililiter vsebuje 200 mg humanega polispecifičnega imunoglobulina, od katerih je vsaj 98 % imunoglobulina tipa G (IgG) Približni odstotek podrazredov IgG je naslednji:
English: The same adverse reactions may occur in the elderly population.
Slovenian: Enaki neželeni učinki se lahko pojavijo pri starejši populaciji.
English: Your doctor will calculate the correct dose for you taking into account your weight and response to treatment.
Slovenian: Zdravnik bo izračunal pravilen odmerek za vas, pri tem pa bo upošteval vašo telesno maso in odziv na zdravljenje.
English: The solution should be clear and pale-yellow or light-brown.
Slovenian: Raztopina mora biti bistra in bledo rumene ali svetlo rjave barve.
English: The hazard ratios (95 % CI) for the lower dose and higher dose compared to placebo was 0.48 (0.27, 0.85) and 0.25 (0.12, 0.49), respectively.
Slovenian: Razmerje tveganja (95 % IZ) je bilo v primerjavi s placebom za nižji odmerek 0,48 (0,27; 0,85), za višji odmerek pa 0,25 (0,12; 0,49).
English: •the testing of each donation and pools of plasma for signs of virus/infections.
Slovenian: •testiranje prisotnosti virusov/okužb v vsaki darovani in zbrani plazmi.
English: Hizentra may impair the effect of some live virus vaccines such as measles, rubella, mumps and chicken pox.
Slovenian: Zdravilo Hizentra lahko zmanjša učinkovitost nekaterih cepiv z živimi virusi, kot so cepiva proti ošpicam, rdečkam, mumpsu in noricam.
English: Hizentra is also used in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a form of autoimmune disease.
Slovenian: Zdravilo Hizentra se uporablja tudi pri bolnikih s kronično vnetno demielinizirajočo polinevropatijo (CIDP), obliko avtoimunske bolezni.
English: All pre-filled syringes have a standard luer lock, which is a screw connection at the syringe tip that creates a leak-free seal.
Slovenian: Vse napolnjene injekcijske brizge imajo standarden luer lock nastavek z navojem na konici brizge, ki zagotavlja dobro tesnjenje.
English: Polysorbate 80
Slovenian: L-prolin polisorbat 80
English: 8 Insert the needle
Slovenian: 8 Vbodite iglo
English: Data from prospective clinical trials on the use of human normal immunoglobulin in breast feeding women is limited.
Slovenian: Podatki iz prospektivnih kliničnih preskušanj o uporabi humanega polispecifičnega imunoglobulina pri doječih ženskah so omejeni.
English: 25 ml/hour/site 50 ml/hour/site 75 ml/hour/site 100 ml/hour/site
Slovenian: 25 ml/uro/mesto 50 ml/uro/mesto 75 ml/uro/mesto 100 ml/uro/mesto
English: Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.
Slovenian: V redkih primerih lahko humani polispecifični imunoglobulini povzročijo nenadno znižanje krvnega tlaka, v posameznih primerih pa anafilaktični šok, tudi kadar bolnik pri predhodni uporabi ni pokazal preobčutljivosti.
English: Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contraindicated.
Slovenian: - hipogamaglobulinemiji in ponavljajočih se bakterijskih okužbah pri bolnikih s kronično limfocitno levkemijo, pri katerih je bila profilaksa z antibiotiki neuspešna ali je kontraindicirana.
English: No differences were seen in the pharmacokinetic parameters between adult and paediatric PID study patients.
Slovenian: V farmakokinetičnih parametrih ni bilo opaznih razlik med odraslimi in pediatričnimi bolniki v študiji PID.
English: Read the package leaflet before use.
Slovenian: samo za subkutano uporabo Pred uporabo preberite priloženo navodilo!
English: • Tiredness (fatigue), including generally feeling unwell (malaise)
Slovenian: • utrujenost, vključno s splošnim slabim počutjem
English: If you forget to use Hizentra If you think you have missed a dose, speak to your doctor as soon as possible.
Slovenian: Če ste pozabili uporabiti zdravilo Hizentra Če mislite, da ste izpustili odmerek, se čim prej posvetujte z zdravnikom.
English: In isolated cases, infusion site ulcer or burning sensation may occur.
Slovenian: V posamičnih primerih se lahko pojavi razjeda na mestu infundiranja ali pekoč občutek.
English: In a clinical phase III trial with Hizentra (n = 46), the subjects achieved sustained trough levels (median 8.1 g/l) over a period of 29 weeks when receiving median weekly doses of 0.06 to 0.24 g/kgbw.
Slovenian: V fazi III kliničnega preskušanja zdravila Hizentra (n = 46) so preiskovanci dolgotrajne najnižje ravni (mediana 8,1 g/l) dosegli v 29 tednih, ko so prejemali mediane tedenske odmerke od 0,06 do 0,24 g/kg TM.
English: If you think you have missed a dose, speak to your doctor as soon as possible.
Slovenian: Če mislite, da ste izpustili odmerek, se čimprej posvetujte z zdravnikom.
English: CSL Behring GmbH D-35041 Marburg Germany
Slovenian: CSL Behring GmbH D-35041 Marburg Nemčija
English: In particular, patients naïve to human normal immunoglobulin, patients switched from an alternative product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse reactions.
Slovenian: Predvsem bolnike, ki še niso prejemali humanega polispecifičnega imunoglobulina, bolnike, ki so na zdravljenje prešli z drugega zdravila, ali bolnike, pri katerih je bila prekinitev od predhodnega infundiranja dolga, je treba spremljati med prvim infundiranjem in še eno uro po njem, da bi ugotovili morebitne neželene učinke.
English: • Fast heartbeat (tachycardia)
Slovenian: • hiter srčni utrip (tahikardija)
English: In clinical studies Hizentra was evaluated in 13 subjects with PID >65 years of age and no specific dose adjustments were necessary to achieve the desired serum IgG levels.
Slovenian: V kliničnih študijah so zdravilo Hizentra ocenjevali pri 13 bolnikih s PID, starih >65 let, in za doseganje želenih ravni protiteles IgG v serumu niso bili potrebni posebni prilagojeni odmerki.
English: Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded.
Slovenian: Kljub tem ukrepom pri zdravilih, pripravljenih iz humane krvi ali plazme, ni mogoče popolnoma izključiti prenosa okužbe.
English: Using smaller needles (i.e. higher gauge number) may make it more difficult to manually push Hizentra.
Slovenian: igel z večjo oznako v G) bo morda ročno potiskanje zdravila Hizentra težje.
English: Pack sizes of 1 or 10 pre-filled syringes: 1 g / 5 ml
Slovenian: Velikosti pakiranja po 1 ali 10 napolnjenih injekcijskih brizg: 1 g/5 ml
English: In clinical studies Hizentra was evaluated in 61 subjects with CIDP >65 years of age and no specific dose adjustments were necessary to achieve the desired clinical outcome.
Slovenian: V kliničnih študijah so zdravilo Hizentra ocenjevali pri 61 bolnikih s CIDP, starih >65 let, in za doseganje želenega kliničnega izida niso bili potrebni posebni prilagojeni odmerki.
English: Treatmentof low immunoglobulin levels and recurrent bacterial infections in patients with chronic lymphocytic leukaemia(CLL), a certain kind of blood cancer, where prophylactic antibiotics have failed or are contra-indicated.
Slovenian: Zdravljenje nizkih ravni imunoglobulinov in ponavljajočih se bakterijskih okužb pri bolnikih s kronično limfocitno levkemijo, določeno vrsto krvnega raka, pri katerih je bila profilaksa z antibiotiki neuspešna ali je kontraindicirana.
English: Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins.
Slovenian: Z uporabo imunoglobulinov so povezani arterijski in venski trombembolični dogodki, vključno z miokardnim infarktom, možgansko kapjo, globoko vensko trombozo in pljučno embolijo.
English: Local reactions at infusion sites: swelling, soreness, redness, induration, local heat, itching, bruising and rash.
Slovenian: Lokalne reakcije na mestih infundiranja: otekanje, bolečina, rdečica, induracija, lokalna vročina, srbenje, modrica in izpuščaj.
English: In all three groups, each infusion parameter was used for 4 weeks, after which subjects successfully completing required minimal number of valid infusions could switch to the next higher infusion parameter.
Slovenian: Po tem obdobju so lahko preiskovanci, ki so uspešno zaključili potrebno minimalno število veljavnih infundiranj, prešli na naslednji višji parameter infundiranja.
English: VIAL
Slovenian: Viale
English: • Flu-like symptoms
Slovenian: • simptomi podobni gripi
English: Simulations with population-pharmacokinetic models in the PATH study suggest that a comparable IgG exposure (Cmax, AUC0-14days, Cmin, 14 days) is achieved when the double weekly Hizentra dose is administered every two weeks in the CIDP subjects.
Slovenian: Simulacije z modeli populacijske farmakokinetike v študiji PATH kažejo, da je mogoče doseči primerljivo izpostavljenost IgG (Cmax, AUC0-14 dni, Cmin, 14 dni), če se daje bolnikom s CIDP dvojni tedenski odmerek zdravila Hizentra vsaka dva tedna.
English: Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus or the neonate are to be expected.
Slovenian: Klinične izkušnje z imunoglobulini kažejo, da ni pričakovati škodljivih učinkov na potek nosečnosti ali na plod ali novorojenčka.
English: Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Slovenian: Občasno se lahko pojavijo neželeni učinki, kot so mrzlica, glavobol, povišana telesna temperatura, bruhanje, alergijske reakcije, navzea, artralgija, nizek krvni tlak in zmerna bolečina v križu.
English: The mean dose administered each week was 0.23 g/kg bw.
Slovenian: Srednja vrednost odmerka, danega vsak teden, je bila 0,23 g/kg TM.
English: A statistically significant lower percentage of subjects treated with Hizentra, 32.8 % for 0.4 g/kg bw and 38.6 % for 0.2 g/kg bw, had CIDP relapse or was withdrawn for other reasons compared with 63.2 % subjects treated with placebo (p < 0.001 or p = 0.007, respectively).
Slovenian: Statistično pomembno manjši odstotek preiskovancev, zdravljenih z zdravilom Hizentra, 32,8 % za odmerek 0,4 g/kg TM in 38,6 % za odmerek 0,2 g/kg TM, je imelo relaps CIDP ali so izstopili iz študije iz drugih razlogov v primerjavi s 63,2 % preiskovancev, zdravljenih s placebom (p < 0,001 oziroma p = 0,007).
English: Pre-filled syringes 5, or 10 ml of solution in a pre-filled syringe (cyclo-olefin-copolymer (COC)).
Slovenian: Napolnjene injekcijske brizge 5 ali 10 ml raztopine v napolnjeni injekcijski brizgi (ciklični olefin kopolimer (COC)).
English: If you are using a syringe pump, Hizentra pre-filled syringes can be placed directly in the syringe pump if the syringe size matches the pump requirements.
Slovenian: Če uporabljate infuzijsko črpalko, lahko napolnjeno injekcijsko brizgo zdravila Hizentra namestite neposredno na črpalko na brizgo, če velikost brizge ustreza zahtevam črpalke.
English: The initial infusion rate should not exceed 20 ml/hour/site.
Slovenian: Začetna hitrost infundiranja naj ne preseže 20 ml/uro/mesto.
English: In the clinical studies Hizentra was evaluated in 13 patients with PID >65 years of age.
Slovenian: V kliničnih študijah je bilo zdravilo Hizentra ovrednoteno pri 13 preiskovancih s PID, starih >65 let.
English: Simulations by empirical Population Pharmacokinetic models suggested that comparable IgG exposure levels (AUC0-14days, Cmin 14days) may be obtained if Hizentra is administered subcutaneously every two weeks using double the weekly dose during maintenance therapy.
Slovenian: Simulacije z empiričnimi modeli populacijske farmakokinetike so pokazale, da je mogoče primerljive ravni izpostavljenosti IgG (AUC0-14dni, Cmin 14dni) doseči, če se daje zdravilo Hizentra subkutano vsaka dva tedna z uporabo dvojnega tedenskega odmerka v času vzdrževalne terapije.
English: Pack sizes of 1, 10 or 20 vials: 1 g / 5 ml
Slovenian: Velikosti pakiranja po 1, 10 ali 20 vial: 1 g/5 ml
English: Hizentra is for subcutaneous use only.
Slovenian: Zdravilo Hizentra uporabljamo samo subkutano.
English: Therefore, Hizentra should only be given with caution to pregnant women.
Slovenian: Zato naj se zdravilo Hizentra nosečnicam daje samo z največjo previdnostjo.
English: The mean dose administered each week was 0.12 g/kg body weight (bw).
Slovenian: Srednja vrednost tedenskega odmerka je bila 0,12 g/kg telesne mase (TM).
English: Therapy should be initiated and monitored under the supervision of a healthcare professional experienced in the treatment of immunodeficiency/CIDP with SCIg.
Slovenian: Zdravljenje naj uvede in spremlja zdravstveni delavec z izkušnjami pri zdravljenju imunske pomanjkljivosti/CIDP s s.c.Ig.
English: Hizentra was evaluated in 68 paediatric subjects with PID 2 to <12 years of age and in 57 paediatric subjects 12 to <18 years of age.
Slovenian: Zdravilo Hizentra je bilo ovrednoteno pri 68 pediatričnih bolnikih s PID, starih od 2 do <12 let, ter pri 57 pediatričnih bolnikih, starih od 12 do <18 let.
English: Follow the steps below and use aseptic technique to administer Hizentra.
Slovenian: Pri apliciranju zdravila Hizentra upoštevajte spodnja navodila in uporabite aseptično tehniko.
English: In the US prospective open label, single arm and multicentre study, a total of 49 subjects with primary immunodeficiency syndromes aged between 5 and 72 years old were treated with Hizentra for up to 15 months.
Slovenian: V prospektivni, odprti, enokračni in multicentrični študiji v ZDA je bilo skupaj 49 preiskovancev s sindromi primarne imunske pomanjkljivosti, starih od 5 do 72 let, zdravljenih z zdravilom Hizentra v obdobju do 15 mesecev.
English: Tell your vaccinating doctor prior to a vaccination about your treatment with Hizentra.
Slovenian: Pred cepljenjem zdravnika, ki vas bo cepil, obvestite o zdravljenju z zdravilom Hizentra.
English: Infusion sites should be at least 5 cm apart.
Slovenian: Mesta infundiranja morajo biti medsebojno oddaljena vsaj 5 cm.
English: In the PATH study, subjects (n = 172) achieved sustained trough levels over a period of 24 weeks when receiving weekly doses of 0.2 g/kg bw and 0.4 g/kg bw, respectively.
Slovenian: V študiji PATH so preiskovanci (n = 172) dosegli vzdrževane najnižje ravni v obdobju 24 tednov, ko so prejemali tedenske odmerke 0,2 g/kg TM oziroma 0,4 g/kg TM.
English: Therefore, after receiving this medicine you may have to wait up to 3 months before receiving your live-attenuated vaccine.
Slovenian: Zato boste morda morali po prejemu tega zdravila cepljenje z živimi oslabljenimi virusi odložiti za vsaj tri mesece.
English: In case of home treatment, this will be initiated by a healthcare professional experienced in the treatment of immunodeficiency/CIDP with SCIg and in the guidance of patients for home treatment.
Slovenian: Zdravljenje na domu uvede zdravstveni delavec z izkušnjami pri zdravljenju imunske pomanjkljivosti/CIDP s s.c.Ig in usposabljanju bolnikov za zdravljenje na domu.
English: • Do not store above 25 °C.
Slovenian: • Zdravilo shranjujte pri temperaturi do 25 ºC.